Hotspots and frontiers in cervical cancer research: A bibliometric and visualization analysis from 2013 to 2022

Abstract

Background: Cervical cancer is a highly aggressive cancer that seriously affects the physical and mental health and quality of life of women, especially for women in developing countries. Therefore, cervical cancer has always been the focus of research, and in recent years, various studies on cervical cancer have emerged one after another.

Methods: Our study aimed to illustrate the development trends in cervical cancer research in China from 2013 to 2022 and compare the findings with studies in other parts of the world during the same period by using bibliometric analysis and the Science Citation Index Expanded. Literature data were analyzed and visualized by using CiteSpace and VOSviewer.

Results: The results show that the number of articles on cervical cancer has increased in recent years, among which articles on the pathogenesis and epidemiological characteristics of cervical cancer account for the majority. The research in China has developed rapidly in recent years, but there is still a certain gap compared with other developed countries.

Conclusion: Bibliometric and visualization analyses offer a unique and objective perspective in the field of cervical cancer and may assist scholars in identifying new research directions.

Keywords

cervical cancer / bibliometric analysis / hotspot / Web of Science

References

[1] Cibula D, Raspollini MR, Planchamp F, et al. ESGO/ESTRO/ESP guidelines for the management of patients with cervical cancer—update 2023. Int J Gynecol Cancer. 2023;33(5):649-666.

[2] Miller KD, Nogueira L, Devasia T, et al. Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin. 2022;72(5):409-436.

[3] Ong SK, Abe SK, Thilagaratnam S, et al. Towards elimination of cervical cancer—human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA) member countries. Lancet Reg Health West Pac. 2023;39:100860.

[4] Ojha PS, Maste MM, Tubachi S, Patil VS. Human papillomavirus and cervical cancer: an insight highlighting pathogenesis and targeting strategies. Virus Dis. 2022;33(2):132-154.

[5] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.

[6] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.

[7] Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and Joinpoint analysis. BMC Public Health. 2021;21(1):1329.

[8] Duan R, Xu K, Huang L, et al. Temporal trends and projection of cancer attributable to human papillomavirus infection in China, 2007–2030. Cancer Epidemiol Biomarkers Prevent. 2022;31(5):1130-1136.

[9] Zheng RS, Zhang SW, Sun KX, et al. [Cancer statistics in China, 2016]. Zhonghua zhong liu za zhi [Chin J Oncol]. 2023;45(3):212-220.

[10] Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(5):584-590.

[11] Wang R, Guo X, Wisman GBA, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis. 2015;15:257.

[12] Zou D, Liang A. A bibliometric analysis on research hot-spot and publication trends in immunotherapy for cervical cancer after surgery. Asian J Surg. 2023;46(8):3178-3179.

[13] Liu Y, Liu Q, Jiang X. Bibliometric analysis of hotspots and frontiers in cancer-related fatigue among ovarian cancer survivors. PLoS ONE. 2022;17(9):e0274802.

[14] He Z, Dai L, Zuo Y, Chen Y, Wang H, Zeng H. Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. Bioengineered. 2022;13(6):14667-14680.

[15] Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724-728.

[16] Luo J, Shi Y, Wang X, et al. A 20-year research trend analysis of the influence of anesthesia on tumor prognosis using bibliometric methods. Front Oncol. 2021;11:683232.

[17] van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-538.

[18] Lai P, Xu S, Xue J, Zhang H, Zhong Y, Liao Y. Current hotspot and study trend of innate immunity in COVID-19: a bibliometric analysis from 2020 to 2022. Front Immunol. 2023;14:1135334.

[19] Deng Z, Luo F, Lin Y, et al. Research trends of mesenchymal stem cells application in orthopedics: a bibliometric analysis of the past 2 decades. Front Public Health. 2022;10:1021818.

[20] Wu H, Cheng K, Tong L, Wang Y, Yang W, Sun Z. Knowledge structure and emerging trends on osteonecrosis of the femoral head: a bibliometric and visualized study. J Orthop Surg Res. 2022;17(1):194.

[21] Huang F, Zheng B, Wu C, et al. International publication trends in low back pain research: a bibliometric and visualization analysis. Front Public Health. 2022;10:746591.

[22] Yeung AWK, Atanasov AG, Sheridan H, et al. Open innovation in medical and pharmaceutical research: a literature landscape analysis. Front Pharmacol. 2021;11:587526.

[23] Wan X, Wang X, Pang R, et al. Mapping knowledge landscapes and emerging trends of the links between osteoarthritis and osteoporosis: a bibliometric analysis. Front Public Health. 2022;10:1019691.

[24] Su Y, Ruan Z, Li S, Li Z, Chang T. Emerging trends and research foci of neuromyelitis optica spectrum disorder: a 20-year bibliometric analysis. Front Immunol. 2023;14:1177127.

[25] Chen J, Chen G, Xu X, Chen L, Zhang J, Liu F. Bibliometric analysis and visualized study of research on autophagy in ischemic stroke. Front Pharmacol. 2023;14:1232114.

[26] Qin Y, Ren S, Shao B, et al. The intellectual base and research fronts of IL-37: a bibliometric review of the literature from WoSCC. Front Immunol. 2022;13:931783.

[27] Schubert M, Bauerschlag DO, Muallem MZ, Maass N, Alkatout I. Challenges in the diagnosis and individualized treatment of cervical cancer. Medicina (Kaunas). 2023;59(5):925.

[28] Sasidharanpillai S, Ravishankar N. The short-term impact of COVID-19 pandemic on cervical cancer screening: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2022;23(5):1497-1504.

[29] Wentzensen N, Clarke MA, Perkins RB. Impact of COVID-19 on cervical cancer screening: challenges and opportunities to improving resilience and reduce disparities. Prev Med. 2021;151:106596.

[30] Guo Y, Peng Q, Wang Y, et al. The application of DNA ploidy analysis in large-scale population screening for cervical cancer. Acta Cytol. 2021;65(5):385-392.

[31] Mijiti Y, Yusupu H, Liu H, et al. Survey on cervical cancer knowledge and its influencing factors among 2,578 women in Shache county, Kashi, China. BMC Womens Health. 2023;23(1):246.

[32] Zhang M, Zhong Y, Wang L, et al. Cervical cancer screening coverage—China, 2018–2019. China CDC Weekly. 2022;4(48):1077-1082.

[33] Zhang F, Li M, Li X, Bai H, Gao J, Liu H. Knowledge of cervical cancer prevention and treatment, and willingness to receive HPV vaccination among college students in China. BMC Public Health. 2022;22(1):2269.

[34] Chen L, Lu F, Wang Z, et al. An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China. Hum Vaccines Immunother. 2023;19(2):2225389.

[35] Ren X, Hao Y, Wu B, et al. Efficacy of prophylactic human papillomavirus vaccines on cervical cancer among the Asian population: a meta-analysis. Front Microbiol. 2022;13:1052324.

[36] Yin X, Zhang M, Wang F, et al. A national cross-sectional study on the influencing factors of low HPV vaccination coverage in mainland China. Front Public Health. 2023;10:1064802.

[37] Davies C, Stoney T, Hutton H, et al. School-based HPV vaccination positively impacts parents’ attitudes toward adolescent vaccination. Vaccine. 2021;39(30):4190-4198.

[38] Brandt HM, Footman A, Adsul P, Ramanadhan S, Kepka D. Implementing interventions to start HPV vaccination at age 9: using the evidence we have. Hum Vaccines Immunother. 2023;19(1):2180250.

[39] Partanen VM, Heinävaara S, Waldstrøm M, et al. Adherence to international recommendations in the governance and organisation of Nordic cervical cancer screening programmes. Acta Oncol. 2020;59(11):1308-1315.

[40] Aoki ES, Yin R, Li K, et al. National screening programs for cervical cancer in Asian countries. J Gynecol Oncol. 2020;31(3):e55.

[41] Senkomago V, Greek A, Jackson JE, Thomas CC, Richardson LC, Benard VB. Learning from cervical cancer survivors: an examination of barriers and facilitators to cervical cancer screening among women in the United States. J Prim Care Commun Health. 2021;12:21501327211041862.

[42] White A, Thompson TD, White MC, et al. Cancer screening test use — United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):201-206.

[43] Xing Y, Yasinjan F, Du Y, et al. Immunotherapy in cervical cancer: from the view of scientometric analysis and clinical trials. Front Immunol. 2023;14:1094437.

[44] Li C, Cang W, Gu Y, Chen L, Xiang Y. The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge. Front Immunol. 2023;14:1195476.

RIGHTS & PERMISSIONS

2024 2024 The Authors. Malignancy Spectrum published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.